above the IC 50 . We therefore synthesized a series of
Introduction activate the adenylyl cyclase activity in the host cell. Therefore, by interrupting the EF-CaM interaction with The association of proteins plays a role in all cellular processes. Protein-protein interactions serve to orgaa small molecule, the pathological effects of EF may be reduced significantly. nize and maintain the cytoskeletal structure in the cell, modulate enzymatic activities, and localize enzymes
The recently solved crystal structure of the EF-CaM complex reveals that the protein-protein interaction is and substrates at discrete positions in the cell. For these reasons, the discovery of small molecules that inhibit quite distinct from other CaM binding proteins [9, 11] . The structures of several complexes of CaM with CaM protein-protein interactions is a goal of many research programs that seek inhibitors for use as reagents in cell binding proteins reveal that the central ␣ helix of CaM is kinked and wrapped around the ␣-helical CaM binding biology and as therapeutics in medicine. This paper reports a strategy that combines cell-based screening domains [11] . However, in the structure of the EF-CaM complex, the central ␣ helix of CaM adopts an extended with protein interaction screening to identify a small conformation surrounded by two domains of EF [9, 10] . molecule that inhibits the activation of edema factor by For this reason, a small molecule that binds to the CaM calmodulin in cells.
binding region of EF may not interfere with the many The identification, or design, of small molecules that other important roles of CaM in cells. inhibit protein-protein interactions is substantially more
To identify a small molecule that inhibits the EF-CaM difficult than is the development of inhibitors targeting interaction, we screened a library containing 10,000 dienzyme active sites or ligand binding pockets [1] . For verse structures using a combination of a cell-based the latter case, the availability of natural ligands and assay and a surface plasmon resonance (SPR) spectrossubstrates provides a good starting point for developing copy-based protein-protein binding assay. This screen inhibitors. Furthermore, active sites of enzymes and liidentified one compound as an inhibitor of the EF-CaM gand binding pockets of receptors are intrinsically complex. In vitro assays showed that the compound matched for binding of small molecules, which can fill targets EF and inhibits the catalytic activity of EF by disrupting the EF-CaM interaction. This initial hit was for inhibition of two unrelated enzymes: ␤-lactamase and ␣-chymotrypsin. Three of the twenty-seven comResults pounds inhibited these unrelated enzymes at a low micromolar range and were excluded from further study.
Screening Strategy
The remaining 24 compounds were then individually To identify candidate inhibitors of EF, we first screened tested using an SPR-based assay to identify molecules a library of molecules in a cell-based assay. We started that act by blocking the association of EF with immobiwith this assay because our ultimate goal was to identify lized CaM ( Figure 1B) . We have previously developed a compounds that were active in cell culture. The assay cutinase-directed method for covalent immobilization reports on a cAMP-triggered morphological change in of functional proteins on self-assembled monolayers Y1 cells, a cultured line of murine adrenocortical cells
[15] and showed that this strategy is useful for quantita-( Figure 1A ) [ of the EF-CaM protein-protein complex in the transcripwithout employing fusion proteins or nuclear localization. tional machinery would result in an enzymatic activity that is toxic to host cells. Using yeast two-hybrid screens
As an inhibitor of a CaM binding protein, 10506-2A is somewhat unusual. Numerous CaM antagonists have in such a system can be complicated. In addition, the cell-based screening method described in this manubeen developed that bind to the hydrophobic surfaces of CaM that are exposed upon Ca 2ϩ binding [24] . However, script uses a more pathologically relevant environment We therefore established the minimal structure-activity relationship and from this information ficity for their target protein over other CaM-activated processes. In our study, we illustrate how three different were able to identify an analog that retained inhibitory activity but was tolerated by cells. Our finding that a assays can be used to establish the target of inhibitors identified in screens. Kinetic studies can reveal competiminor structural change gave a significant reduction in cytotoxicity suggests that the inhibitors may be further tive binding of the small molecule for one of the protein targets. Fluorescence studies, for small molecules that enhanced with minimal modifications. have a strong fluorescence mode, may reveal the protein that is bound by the inhibitor. Finally, photolabeling Significance studies provide the strongest evidence for identifying the site of action of a small molecule IPPI.
In this paper, we have reported a screening strategy to identify a small molecule inhibitor of the EF-CaM ical labeling yields were 10%-30% when analyzed using analytical HPLC. Proteolysis reactions were done by mixing the samples with unless otherwise indicated. CaM titrations were performed in the presence of 10 mM free Mg 2ϩ , 2 M free Ca 2ϩ , and 10 mM EGTA. ArgC (0.5 g/ml), TLCK-treated ␣-chymotrypsin (10 g/ml), or TPCKtreated trypsin (0.1 g/ml) at 37ЊC for 3 hr. Digested peptides were Concentrations of free ions were calculated using the MAXC program (http://www.stanford.edu/‫ف‬cpatton/max.html). ATP and cAMP then mixed with an equal volume of sinapinic acid or 2,5-dihydroxybenzoic acid (10 mg/ml in 50% acetonitrile, 0.2% trifluoroacetic were separated by Dowex and alumina columns [21] . Sf9 cell membrane containing type I adenylyl cyclase was prepared and assays acid) and analyzed using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. Peaks were were performed as described [28] . DMSO was limited to 1% v/v to avoid inhibition of cyclases. Kinetic measurements of ␤-lactamase assigned using Peptidemass (http://us.expasy.org/tools/peptidemass.html) allowing for one to two missed cuts. were performed as described [16] . Effects of 10506-2A on the cataly-
